DEVELOPMENT OF HSV VECTORS FOR TREATMENT OF INHERITED DISEASES
用于治疗遗传性疾病的 HSV 载体的开发
基本信息
- 批准号:6602408
- 负责人:
- 金额:$ 10.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-01 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:Epstein Barr virus Escherichia coli gene expression gene targeting gene therapy genetic promoter element genetic transduction herpes simplex virus 1 hypoxanthine phosphoribosyltransferase laboratory mouse latent virus infection method development transfection /expression vector transposon /insertion element virus replication
项目摘要
Herpes Simplex Virus, type 1 (HSV-1) is an enveloped DNA virus that replicates in the nucleus. While HSV is most often found in nature in a latent state in sensory neurons, it efficiently infects and expresses its genome in a very large number of different cell types and tissues. The HSV genome and capsid are also known to accommodate relatively large DNA inserts. Therefore, as a gene delivery vehicle HSV can be used to efficiently vector relatively large or multiple transgenes into a wide range of cell and tissue type. Wild-type HSV is a rapidly growing and very destructive virus, due to activities it encodes that augment or perturb almost every aspect of host cell metabolism. These functions are largely provided by the immediate early (IE) proteins of the virus. A major goal of the previous funding period was to abrogate the expression of HSV IE proteins, provide the means to efficient propagate multiple IE mutants, and evaluate the potential of multiple IE gene knock out viruses as gene delivery vehicles. This systematical undertaking ultimately resulted in the derivation of a whole genome based vector (d109) that; 1. does not express any IE genes, 2. is completely non-toxic to cells, 3. can be obtained in relatively high titers, 4. efficiently delivers its genome to the nucleus, and 5. persists in infected cells for prolonged periods of time. We also found that because this vector does not express any of the HSV activator proteins, transgene expression is fairly low, and that parts of vector genome may integrate into cellular DNA (f= approximately 1%). The goal of this proposal is to complete the development and characterization of the HSV replication-defective vector system for it uses as a general DNA vectoring and expression system. As model transgenes we will use GFP, neo/I, tk and HPRT, and propose 3 specific aims; 1. Methods will be developed to more efficiently insert prospective transgenes and promoters into the vector backbone for evaluation and use. 2. Rational strategies for augmenting or regulating transgene expression in vivo and in vitro will be explored. We will also examine the ability of vector strains of HSV to reactivate previous latent wild type HSV in vivo. 3. The interaction between the vector and cellular genome will be investigated with respect to random insertion, biochemical transformation, and the potential use of HSV as a vector to efficiently deliver genomic DNA for the purpose of promoting homologous recombination between the virus and cell. These latter experiments have implications for the use of HSV to alter cells in an inheritable way, and/or to precisely knock out or repair cellular genes.
单纯疱疹病毒 1 型 (HSV-1) 是一种在细胞核中复制的有包膜 DNA 病毒。虽然 HSV 在自然界中最常以潜伏状态存在于感觉神经元中,但它可以有效地感染大量不同的细胞类型和组织并在其中表达其基因组。还已知 HSV 基因组和衣壳可容纳相对较大的 DNA 插入片段。因此,作为基因递送载体,HSV可用于有效地将相对较大或多个转基因导入多种细胞和组织类型中。野生型 HSV 是一种快速生长且极具破坏性的病毒,因为它编码的活性几乎增强或扰乱了宿主细胞代谢的各个方面。这些功能主要由病毒的立即早期(IE)蛋白提供。上一资助期的主要目标是消除 HSV IE 蛋白的表达,提供有效繁殖多种 IE 突变体的方法,并评估多种 IE 基因敲除病毒作为基因传递载体的潜力。这项系统性工作最终产生了基于全基因组的载体(d109): 1. 不表达任何 IE 基因,2. 对细胞完全无毒,3. 可以以相对较高的滴度获得,4. 有效地将其基因组递送至细胞核,并且 5. 在受感染的细胞中持续较长时间。我们还发现,由于该载体不表达任何 HSV 激活蛋白,因此转基因表达相当低,并且载体基因组的部分可能整合到细胞 DNA 中(f=约 1%)。本提案的目标是完成 HSV 复制缺陷型载体系统的开发和表征,使其用作通用 DNA 载体和表达系统。作为模型转基因,我们将使用 GFP、neo/I、tk 和 HPRT,并提出 3 个具体目标; 1. 将开发方法以更有效地将预期转基因和启动子插入载体骨架中以进行评估和使用。 2. 将探索增强或调节体内和体外转基因表达的合理策略。我们还将检查 HSV 载体株在体内重新激活先前潜伏的野生型 HSV 的能力。 3. 将研究载体与细胞基因组之间的相互作用,包括随机插入、生化转化以及HSV作为载体有效递送基因组DNA以促进病毒与细胞之间同源重组的潜在用途。后面的这些实验对于使用 HSV 以可遗传的方式改变细胞和/或精确敲除或修复细胞基因具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Neal A. DeLuca其他文献
Neal A. DeLuca的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Neal A. DeLuca', 18)}}的其他基金
Modulation and Utilization of RNA Polymerase III by Herpes Simplex Virus
单纯疱疹病毒对 RNA 聚合酶 III 的调节和利用
- 批准号:
10302317 - 财政年份:2020
- 资助金额:
$ 10.37万 - 项目类别:
DEVELOPMENT OF HSV VECTORS FOR TREATMENT OF INHERITED DISEASES
用于治疗遗传性疾病的 HSV 载体的开发
- 批准号:
6471782 - 财政年份:2001
- 资助金额:
$ 10.37万 - 项目类别:
Molecular Microbial Persistance and Pathogenesis
分子微生物的持久性和发病机制
- 批准号:
7826955 - 财政年份:2001
- 资助金额:
$ 10.37万 - 项目类别:
Molecular Microbial Persistance and Pathogenesis
分子微生物的持久性和发病机制
- 批准号:
8066401 - 财政年份:2001
- 资助金额:
$ 10.37万 - 项目类别:
相似国自然基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
- 批准号:32302245
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
- 批准号:82371775
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
- 批准号:31871817
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
- 批准号:81873549
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的分子机制
- 批准号:31571933
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
超高压诱导牛肉中Escherichia coli O157:H7亚致死损伤及其修复研究
- 批准号:31371861
- 批准年份:2013
- 资助金额:15.0 万元
- 项目类别:面上项目
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的机制
- 批准号:31371845
- 批准年份:2013
- 资助金额:15.0 万元
- 项目类别:面上项目
高密度二氧化碳致死Escherichia coli的相关蛋白质确证及其结构变化研究
- 批准号:31171774
- 批准年份:2011
- 资助金额:66.0 万元
- 项目类别:面上项目
相似海外基金
Measuring biological activity during compound accumulation in Escherichia coli using time-course gene expression profiles
使用时程基因表达谱测量大肠杆菌中化合物积累过程中的生物活性
- 批准号:
449464 - 财政年份:2020
- 资助金额:
$ 10.37万 - 项目类别:
Studentship Programs
Post-Exponential Phase Gene Expression in Escherichia coli
大肠杆菌中指数后期基因表达
- 批准号:
RGPIN-2015-06187 - 财政年份:2019
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual
Post-Exponential Phase Gene Expression in Escherichia coli
大肠杆菌中指数后期基因表达
- 批准号:
RGPIN-2015-06187 - 财政年份:2018
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual
Post-Exponential Phase Gene Expression in Escherichia coli
大肠杆菌中指数后期基因表达
- 批准号:
RGPIN-2015-06187 - 财政年份:2017
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual
Post-Exponential Phase Gene Expression in Escherichia coli
大肠杆菌中指数后期基因表达
- 批准号:
RGPIN-2015-06187 - 财政年份:2016
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual
Post-Exponential Phase Gene Expression in Escherichia coli
大肠杆菌中指数后期基因表达
- 批准号:
RGPIN-2015-06187 - 财政年份:2015
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual
Stationary Phase Gene Expression in Escherichia coli
大肠杆菌中的稳态基因表达
- 批准号:
466812-2014 - 财政年份:2014
- 资助金额:
$ 10.37万 - 项目类别:
University Undergraduate Student Research Awards
Development of gene expression-metabolic model of Escherichia coli
大肠杆菌基因表达代谢模型的建立
- 批准号:
22860056 - 财政年份:2010
- 资助金额:
$ 10.37万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Signal transduci ion and control of gene expression regarding glucose metabolism in Escherichia coli
大肠杆菌中葡萄糖代谢的信号转导和基因表达控制
- 批准号:
13480227 - 财政年份:2001
- 资助金额:
$ 10.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Studies on catalase gene expression in Escherichia coli
大肠杆菌过氧化氢酶基因表达的研究
- 批准号:
9600-1991 - 财政年份:1993
- 资助金额:
$ 10.37万 - 项目类别:
Discovery Grants Program - Individual